AG
PACB icon

Algert Global’s Pacific Biosciences PACB Stock Holding History

Algert Global’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-273,557
Closed -$323K – 1307
2025
Q1 		$323K Hold
273,557
– – 0.01% 994
2024
Q4 		$501K Buy
273,557
+22,361
+9% +$43.6K 0.01% 909
2024
Q3 		$427K Sell
251,196
-89,870
-26% -$148K 0.01% 931
2024
Q2 		$467K Buy
341,066
+161,066
+89% +$325K 0.02% 941
2024
Q1 		$675K Buy
180,000
+150,640
+513% +$882K 0.03% 710
2023
Q4 		$288K Buy
+29,360
New +$240K 0.01% 946
2022
Q3 		– Sell
-33,340
Closed -$147K – 1293
2022
Q2 		$147K Buy
+33,340
New +$203K 0.01% 1066
2021
Q4 		– Sell
-12,111
Closed -$309K – 1073
2021
Q3 		$309K Buy
12,111
+991
+9% +$29.4K 0.04% 750
2021
Q2 		$389K Buy
+11,120
New +$323K 0.13% 223

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Algert Global's PACB Position: Q2 2025 in Review

Algert Global sold out of Pacific Biosciences (PACB) in Q2 2025, closing a stake of 273,557 shares — an estimated $323K sold.

Algert Global first reported a position in PACB in Q2 2021 and held it in 9 quarters. The position peaked at $675K in Q1 2024. 207 funds tracked by Wall St. Rank hold PACB as of Q2 2025.

  • Algert Global reported no remaining Pacific Biosciences position as of Q2 2025 after selling out during the quarter.
  • Algert Global sold 273,557 Pacific Biosciences shares in Q2 2025, an estimated $323K.
  • Algert Global first reported a position in Pacific Biosciences in Q2 2021 and held it in 9 quarters.
  • Algert Global's Pacific Biosciences position peaked at $675K in Q1 2024.
  • 207 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2025.

Based on Algert Global's 13F filing for Q2 2025, filed 14 Aug 2025.